Head to Head Review: Nexalin Technology (NXL) & Its Peers

Nexalin Technology (NASDAQ:NXLGet Free Report) is one of 76 public companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Nexalin Technology to related businesses based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, profitability, dividends and risk.

Insider & Institutional Ownership

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 27.7% of Nexalin Technology shares are owned by insiders. Comparatively, 15.0% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Nexalin Technology and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nexalin Technology $110,000.00 -$4.65 million -1.09
Nexalin Technology Competitors $987.63 million $83.11 million -6.98

Nexalin Technology’s competitors have higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Nexalin Technology and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nexalin Technology -3,088.12% -154.84% -122.94%
Nexalin Technology Competitors -152.14% -47.45% -5.33%

Analyst Recommendations

This is a summary of recent recommendations for Nexalin Technology and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexalin Technology 0 0 0 0 N/A
Nexalin Technology Competitors 246 766 2027 101 2.63

As a group, “Electromedical equipment” companies have a potential upside of 23.96%. Given Nexalin Technology’s competitors higher probable upside, analysts clearly believe Nexalin Technology has less favorable growth aspects than its competitors.

Risk & Volatility

Nexalin Technology has a beta of 5.13, indicating that its share price is 413% more volatile than the S&P 500. Comparatively, Nexalin Technology’s competitors have a beta of 12.49, indicating that their average share price is 1,149% more volatile than the S&P 500.

Summary

Nexalin Technology competitors beat Nexalin Technology on 8 of the 10 factors compared.

Nexalin Technology Company Profile

(Get Free Report)

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.